Ashwin Patkar, MD
Psychiatry · Raleigh, NCNPI 1376627265
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,568 of the $103,167 with a category attached, or 65.5%. 46 manufacturers reported payments, led by Johnson & Johnson at 37.2% of the total. Reporting peaked in 2019 at $55,586 and has fallen 92.4% since, to $4,231 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,125 payments — averaging $91.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$38K
- Otsuka America Pharmaceutical, Inc.$38K
- MDD US Operations, LLC$6K
- Indivior Inc.$4K
- AbbVie$3K
- Sage Therapeutics, LLC$3K
- plus $11K from 40 others
Across 1 payment — averaging $66,610 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$67K
What the payments were for
- Consulting fees$8,0008%
- Speaking & faculty fees$67,56865%
- Travel & lodging$9,1049%
- Food & beverage$18,43718%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$37,214
- REXULTI$36,546
- Lucemyra/Lofexidine$5,431
- SUBLOCADE$3,600
- ZULRESSO$2,631
- INGREZZA$241
- VNS Therapy Symmetry Model 8103 Generator$133
- LATUDA$121
- QELBREE$118
- INVEGA TRINZA$111
- INVEGA SUSTENNA$111
- VRAYLAR$100
How this compares
$103,167 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $134,239 |
| VraylarCariprazine Hcl | 12 | $17,080 |
| FetzimaLevomilnacipran Hcl | 17 | $13,151 |
| Tranylcypromine Sulfate | 16 | $5,575 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $2,049 |
| Duloxetine Hcl | 39 | $1,631 |
| Oxazepam | 16 | $1,272 |
| Clomipramine Hcl | 17 | $1,057 |
| Clonazepam | 32 | $828 |
| Asenapine Maleate | 14 | $702 |
| Gabapentin | 49 | $569 |
| Lamotrigine | 52 | $485 |
| Bupropion Hcl SrBupropion Hcl | 29 | $451 |
| Buspirone Hcl | 25 | $363 |
| Venlafaxine Hcl | 25 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $807 | $134,23918 claims |
| AbbVieVraylar, Fetzima | $3,351 | $30,23129 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $19819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Raleigh
- Robert MilletRaleigh$476K
- Richard WeislerRaleigh$108K
- Mona GuptaRaleigh$88K
- Kellie TolinRaleigh$31K
- Celso LobaoRaleigh$28K
- Elizabeth CoxRaleigh$24K
- Myleme HarrisonRaleigh$13K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.